PD-1 expression on tumour-infiltrating cells is a prognostic factor for relapsed or refractory diffuse large B-cell lymphoma.
Fumiya WadaKimimori KamijoYoshimitsu ShimomuraDaisuke YamashitaShigeo HaraTakayuki IshikawaPublished in: Immunology (2023)
We determined the clinical impact of microenvironmental PD-1 expression and its relationship with neoplastic or microenvironmental expression of PD-L1 in patients with R/R DLBCL. The expression of PD-1 and PD-L1 in the TME dramatically changes during the chemotherapy. Therefore, evaluating TME at relapse, not at diagnosis is useful to predict the outcomes of R/R DLBCL patients.
Keyphrases
- diffuse large b cell lymphoma
- poor prognosis
- prognostic factors
- epstein barr virus
- end stage renal disease
- binding protein
- chronic kidney disease
- acute lymphoblastic leukemia
- induced apoptosis
- newly diagnosed
- ejection fraction
- radiation therapy
- adipose tissue
- skeletal muscle
- oxidative stress
- peritoneal dialysis
- multiple myeloma
- rectal cancer